Venue

European Parliament, Brussels, ASP 1G2

Topics

16:30-16:45 Opening by MEP Stelios Kouloglou

16:45 – 17:45 Panel 1 – Coordination Mr Graham De Barra, Help not Harm, Ireland

Areas of Treatment with medical cannabis/ Medical Cannabis status in Europe and the world

  • Alessandro Piccioli, EPRS Brussels – Presentation of the EPRS study on medical cannabis legal status in EU
  • Dimos Fotopoulos, OKANA vice president, Greece –
  • Dominique Lossignol, Specialist in cancer and pain treatment prescribes medical cannabis to patients/Chef de Clinique a l Institut Bordet, Belgique –
  • Bertrand Rambaud, Président de l’Union Francophone de Cannabinoides dans la médicine, France – Potentiel thérapeutique et expériences personnelles
  • Giorgos Oikonomopoulos, ELEFSYNA, Greece –
  • Majda Robić WORLD HEMP CONGRESS CEO, NGO Agri Lobbyist, Slovenia- Resolving EU hemp legal barriers for health and business
  • Pavel Kubu, International Cannabis and Cannabinoids Institute, Czech Republic –
  • Jaqueline Poitras, MAMAKA, Athens –

17:45 – 18:40 Panel 2 Coordination MEP Katerina Konecna

Best Practices in other countries / Difficulties and Perspectives

  • Dr Franjo Grotenhemen, President of the International Association for cannabinoids in medicine/ chairman of the Medical Cannabis Declaration, Germany – Germany s new program on medical cannabis – Medical Cannabis declaration
  • Saul Kaye, iCan, Cannatech, Israel – Research and regulatory environment in Israel and the breakthroughs in technology and cannatech
  • Graham De Barra, Help not Harm, Ireland
  • Petros Evdokas, Friends of Cannabis Cyprus, –
  • Carola Perez, Observatorio Español de cannabis medicinal, Spain – Presentation on the Spanish Observatory for Medicinal Cannabis and the current situation of cannabis dispensation in Spain
  • Manuel Guzman, Observatorio Español de cannabis medicinal, Spain – Some current new areas of research on medicinal cannabis.

18:40-18:50 Closing Remarks by MEP Stefan Eck

18:50-19:00 Questions and Answers

For registration and information, please contact: [email protected]